Abstract: The interleukin-6 (IL-6) family of cytokines is thought to be involved in the development and regeneration of peripheral nerves; however, their roles in myelination remain unclear. In this study, we examined the effects of IL-6 on the expression of genes for compact myelin proteins using Schwann cell cultures prepared by multiple explantation of adult rat sciatic nerves. In semi-quantitative reverse transcription-polymerase chain reaction analysis, stimulation of Schwann cells with IL-6 significantly increased the mRNA level of peripheral myelin protein 22 (PMP22), but not those of myelin protein zero and myelin basic protein. The increase in PMP22 mRNA was markedly suppressed by AG490, a Janus kinase 2 (JAK2) inhibitor, but not significantly by PD098059, a mitogen-activated protein kinase kinase inhibitor. Immunocytochemical staining revealed that IL-6 enhanced immunoreactivities for the phosphorylated forms of both JAK2 and signal transducer and activator of transcription 3 (STAT3), as well as that for PMP22. These results indicate that IL-6 can enhance PMP22 production in Schwann cells via a JAK2-dependent pathway by probably activating STAT3 and thus may contribute to myelination. E-mail address: shigeruy@med.kanazawa-u.ac.jp (S. Yokoyama).
Interleukin-6 upregulates the expression of PMP22 in cultured rat Schwann cells via a JAK2-dependent pathway
Myelin synthesis by Schwann cells is an important process in the regeneration of injured peripheral nerves as well as in the normal development of the peripheral nervous system (PNS) [4, 9, 12] . It is well known that myelination by Schwann is regulated by various endogenous modulators including extracellular matrix proteins, neurotrophic factors, and cytokines [3, 4] . Of these, interleukin-6 (IL-6) and its related cytokines, such as ciliary neurotrophic factor, leukemia inhibitory factor, and interleukin-11, are particularly important, because mice depleted of the glycoprotein-130 (gp130) gene, which encodes a common receptor subunit for these cytokines, exhibit degeneration of peripheral myelin sheath [2] . As already established in non-neuronal tissues, the IL-6 family of cytokines exert their effects through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and RAS/mitogen-activated kinase (RAS/MAPK) pathways [6, 11] . The balance or interplay of these pathways is thought to determine the cell type-specific responses [6, 11] . Although receptor subunits specific for these cytokines and gp130 are expressed in Schwann cells [10, 13, 20] , very little is known about their downstream effector molecules [14, 28] .
IL-6 is involved in various pathophysiological processes in the PNS [8, 29] . Several studies have demonstrated that the expression of IL-6 and IL-6 receptor  subunit (IL-6R) is upregulated in dorsal root ganglion (DRG) neurons after axonal injury and elongation [8, 13, 17, 19, 22, 26] . However, the biological actions of IL-6-signaling on Schwann cells have not fully been elucidated. We previously found out that IL-6 increased mRNA level of peripheral myelin protein 22 (PMP22) in cultured rat Schwann cells [19] . To further clarify the role of IL-6 in the peripheral myelin synthesis, we examined the effects of IL-6 on other myelin-associated proteins and gp130-mediated signaling pathways using cultured Schwann cells.
Schwann cells were cultured from rat sciatic nerves by the multiple explantation method as described previously [16, 19] Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C in a humidified incubator containing 5% CO 2 . Fibroblast cells were depleted by transferring the explants using fine forceps to new dishes every week. After repeating this procedure 4-5 times, cells that migrated out of the explants were replated on poly-L-lysine-coated 60-mm dishes, and expanded in DMEM containing 10% FCS, 20 µg/ml bovine pituitary extract (KURABO, Osaka, Japan) and 2 µM forskolin (Sigma, St.Louis, MO).
The purity of Schwann cells were assessed by immunocytochemical staining for S100
calcium-binding protein (S100) as follows. After removing the medium, cells were sequentially incubated in (1) 4% paraformaldehyde (PFA); (2) treatment with recombinant rat IL-6 (0.5 µg/ml) for 12 h, as described in [5, 15] .
The expression of IL-6R, gp130, myelin protein zero (MPZ), myelin basic protein (MBP), PMP22, and cyclophilin (CYC) was analyzed by reverse transcription (RT)-polymerase chain reaction (PCR) as previously described [19] . The primer sequences, annealing temperatures, and expected product sizes are given in Table 1 .
The reaction products were electrophoresed through a 1.5% agarose gel, and were visualized by staining with ethidium bromide. The amplified cDNAs for IL-6R, gp130, MPZ, MBP, PMP22, and CYC were further cloned into a pCR2.1-TOPO vector (Invitrogen)
to yield pCIL6R, pCGP130, pCMPZ, pCMBP, pCPMP22, and pCCYC, respectively; the cDNA inserts were verified by nucleotide sequencing. In addition to ethidium bromide-staining, the PCR products were confirmed by Southern blot hybridization analysis as described previously [19] . The probes used were the 250-bp HinfI ( for rat IL-6R, M92340 for rat gp130, K03242 for rat MPZ, NM_017026 for rat MBP, NM_017037 for rat PMP22, and M19533 for rat CYC), and represent the 5′-terminal nucleotide generated by restriction endonuclease cleavage. Autoradiography was carried out at room temperature using an intensifying screen. Band intensities were quantified by densitometric scanning using the Scion Image program (Sion Corp., Frederick, MD), and were normalized to those for CYC mRNA. All data are expressed as the mean ± standard error of the mean (SEM). Data from several conditions were compared by unpaired Student's t test. p values less than 0.05 were considered statistically significant.
Immunoperoxidase staining for IL-6R subunits and myelin-associated proteins was performed as described above for S100 protein, except that cells were permeabilized with Amersham Biosciences) for pJAK2 and pSTAT3.
Figure1A shows Schwann cells purified from adult rat sciatic nerve. At least 98% of the cells were positive for S100, a Schwann cell-specific marker [12] . RT-PCR analysis of total cellular RNA indicated that the mRNAs for IL-6R and gp130 were present in these cells (Fig. 1B ).
Using this Schwann cell culture, we examined the effects of IL-6 on mRNA levels for MPZ, MBP, and PMP22 by RT-PCR combined with Southern blot hybridization. Relative intensities for MPZ mRNA levels were 0.50 ± 0.35 (n = 3), 0.80 ± 0.23 (n = 3), and 0.57 ± 0.56 (n = 3), when IL-6 was added at concentrations of 0.1, 0.5, and 1.0 g/ml, respectively; these values were not significantly high compared with that obtained in the absence of IL-6 (0.49 ± 0.42, n = 3; p > 0.05; Fig. 2A and B). The intensities for MBP mRNA were also not significantly changed (p > 0.05; Fig. 2A and B) ; the values were 1.10 ± 0.71 (n = 3) in the absence of IL-6; 0.48 ± 0.23 (n = 3) at 0.1 g/ml; 1.01 ± 0.57 (n = 3) at 0.5 g/ml; and 0.78 ± 0.49 (n = 3) at 1.0 g/ml. In contrast, PMP22 mRNA levels were significantly elevated at 0.5 and 1.0 µg/ml (1.56 ± 0.75, n = 8; and 1.74 ± 1.01, n = 8, respectively) compared with those cells cultured without IL-6 (0.61 ± 0.14, n = 8; p < 0.05; Fig. 2A and B) . These results confirm the previous data obtained by utilizing glyceraldehyde-3-phosphate dehydrogenase as an internal control [19] , and indicates that IL-6 preferentially acts on PMP22 expression.
We next examined intracellular signaling pathway(s) involved in the elevation of PMP22 mRNA by pretreating Schwann cells with a JAK2 or MAPKK inhibitor. As shown in To confirm the above findings, we performed immnocytochemical staining. As shown in Fig. 4A and B, addition of IL-6 enhanced PMP22-immunoreactivity (IR) in Schwann cells.
IR for pJAK2, an active form of JAK2, was barely detectable in cells cultured without IL-6
( Fig. 4C ), but was prominent in cells stimulated with IL-6 (Fig. 4D ). In addition, IR for pSTAT3, an active form of STAT3, was steadily detected in the nucleus of IL-6-treated cells, but only weakly in untreated cells ( Fig. 4E and F) , indicating that IL-6 activated the JAK2/STAT3 signaling pathway in Schwann cells.
The present study in cultured rat Schwann cells has shown that IL-6 elevates the mRNA level of PMP22 but not those of MPZ and MBP, and that the increase in PMP22 mRNA is JAK2 inhibitor-sensitive and accompanied by phosphorylation of JAK2 and STAT3. These results suggest the involvement of the JAK/STAT pathway in PMP22 expression.
PMP22 is a tetraspan glycoprotein vigorously produced by myelinating Schwann cells [9, 18, 24, 25] . Despite its abundant presence in the compact myelin, the physiological role of PMP22 has not been fully clarified. In good correlation with myelin formation, PMP22
expression in sciatic nerve is strongly upregulated during the postnatal period [9, 18, 24, 25] and during nerve regeneration after injury [9, 24, 25] . Duplication of the PMP22 genes is associated with hereditary demyelinating neuropathies, such as Charcot-Marie-Tooth disease type 1A , and deletion of a single gene copy leads to hereditary neuropathy with liability to pressure palsies [25] . Amici et al. (2006) recently demonstrated that PMP22 exists in a complex with 64 integrin and laminin, suggesting its involvement in the interaction between Schwann cells and the surrounding basal lamina [1] . Therefore, together with the observation that conditional knockout of the mouse gp130 gene caused degeneration of myelin sheath [2] , we surmise that IL-6 signaling through the gp130/JAK/STAT pathway may regulate PMP22 expression and thereby contribute to the formation or stabilization of the compact myelin.
Earlier studies have revealed that PMP22 expression is regulated transcriptionally by cyclic AMP [25] and post-transcriptionally by microRNA-29a [27] . The relationship between these regulatory processes and the present results is currently unclear. In DRG neurons, levels of IL-6 mRNA and IL-6 increase rapidly within a day and gradually decreases over 1-2 weeks after transection and elongation of sciatic nerve [8, 19, 22] . Also, Sheu et al. have shown that phosphorylation of STAT3 in both proximal and distal ends peaks within a day but remains for more than 2 weeks [23] . In contrast, the PMP22 mRNA level declines immediately after nerve injury and then is upregulated after 1 week [24] .
Conceivably, the IL-6-signaling through the gp130/JAK/STAT pathway may participate in the delayed upregulation of PMP22; however, the initial reduction could not be explained by the same mechanism. More detailed analysis is required to determine the contribution of the IL-6 and gp130/JAK/STAT signaling to the peripheral nerve regeneration.
In conclusion, we have demonstrated that IL-6 can upregulate PMP22 expression through a JAK2-dependent pathway. If this pathway is critical for in vivo myelin synthesis, the recent challenges for pharmacological interventions targeting the gp130-mediated signaling [7] might benefit the treatment of neuropathies associated with abnormal myelin formation. Also, upon Schwann cell transplantation into an injured nerve [21] , it would be important to control the gp130/JAK/STAT pathway to ensure proper myelination. 
